Yumanity Therapeutics snags $45 mln Series A
Yumanity Therapeutics, a drug developer focused on diseases caused by protein misfolding, has raised $45 million in Series A funding. Fidelity Management & Research Company led the round with participation from Redmile Group, Alexandria Venture Investments, Biogen, Sanofi-Genzyme BioVentures and Dolby Family Ventures.
10 February 2016•4 mins read
